Literature DB >> 8174418

Tissue-specific alterations of binding sites for peripheral-type benzodiazepine receptor ligand [3H]PK11195 in rats following portacaval anastomosis.

V L Rao1, R Audet, G Therrien, R F Butterworth.   

Abstract

Kinetics of binding of [3H]PK11195, an antagonist ligand with high selectivity for the peripheral-type (mitochondrial) benzodiazepine receptor (PTBR), was studied in homogenates of cerebral cortex, kidney, heart, and testis of portacaval shunted rats and sham-operated controls. Portacaval anastomosis resulted in a significant two- to threefold increase in the number of [3H]PK11195 binding sites in cerebral cortex and kidney. A reduction in the number of [3H]PK11195 binding sites was observed in testis preparations, while the number of binding sites in the heart remained unaltered. These differences in the response of PTBRs to portacaval anastomosis, in different organs suggest that the physiological function of these receptors and the factors regulating them are modulated by distinct mechanisms. The finding of increased densities of [3H]PK11195 binding sites in brain and kidney following portacaval anastomosis parallels the cellular hypertrophy in these tissues and, together with previous observations of similar increases of these binding sites in brain and kidney in congenital hyperammonemia, suggest a pathophysiologic role for ammonia in these changes. In contrast, the significant loss of [3H]PK11195 binding sites in testicular preparations following portacaval anastomosis together with the known effects of steroid hormones on these sites suggests a role for PTBRs in the pathogenesis of testicular atrophy in chronic liver disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8174418     DOI: 10.1007/bf02087558

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  32 in total

1.  Portacaval shunt in the rat.

Authors:  S H LEE; B FISHER
Journal:  Surgery       Date:  1961-10       Impact factor: 3.982

2.  The peripheral-type benzodiazepine receptor is functionally linked to Leydig cell steroidogenesis.

Authors:  V Papadopoulos; A G Mukhin; E Costa; K E Krueger
Journal:  J Biol Chem       Date:  1990-03-05       Impact factor: 5.157

3.  The astrocyte response in experimental portal-systemic encephalopathy: an electron microscopic study.

Authors:  M D Norenberg; L W Lapham
Journal:  J Neuropathol Exp Neurol       Date:  1974-07       Impact factor: 3.685

4.  Ammonia-induced alterations in glutamate and muscimol binding to cerebellar synaptic membranes.

Authors:  V L Rao; A K Agrawal; C R Murthy
Journal:  Neurosci Lett       Date:  1991-09-16       Impact factor: 3.046

Review 5.  Drug interactions at the GABA receptor-ionophore complex.

Authors:  R W Olsen
Journal:  Annu Rev Pharmacol Toxicol       Date:  1982       Impact factor: 13.820

6.  Testicular atrophy in rats with portacaval anastomosis.

Authors:  E Dordal; S Glagov; T S Debarros
Journal:  Arch Pathol       Date:  1967-01

7.  Endogenous benzodiazepine receptor ligands in human and animal hepatic encephalopathy.

Authors:  M Olasmaa; J D Rothstein; A Guidotti; R J Weber; S M Paul; S Spector; M L Zeneroli; M Baraldi; E Costa
Journal:  J Neurochem       Date:  1990-12       Impact factor: 5.372

8.  The GABAA receptor complex in hepatic encephalopathy. Autoradiographic evidence for the presence of elevated levels of a benzodiazepine receptor ligand.

Authors:  A S Basile; N L Ostrowski; S H Gammal; E A Jones; P Skolnick
Journal:  Neuropsychopharmacology       Date:  1990-02       Impact factor: 7.853

9.  Benzodiazepines that bind at peripheral sites inhibit cell proliferation.

Authors:  J K Wang; J I Morgan; S Spector
Journal:  Proc Natl Acad Sci U S A       Date:  1984-02       Impact factor: 11.205

10.  Increased densities of binding sites for the peripheral-type benzodiazepine receptor ligand [3H]PK 11195 in congenital ornithine transcarbamylase-deficient sparse fur mouse.

Authors:  V L Rao; I A Qureshi; R F Butterworth
Journal:  Pediatr Res       Date:  1993-12       Impact factor: 3.756

View more
  6 in total

Review 1.  Alterations of neurotransmitter-related gene expression in human and experimental portal-systemic encephalopathy.

Authors:  R F Butterworth
Journal:  Metab Brain Dis       Date:  1998-12       Impact factor: 3.584

Review 2.  Neurotransmitter dysfunction in hepatic encephalopathy: new approaches and new findings.

Authors:  R F Butterworth
Journal:  Metab Brain Dis       Date:  2001-06       Impact factor: 3.584

3.  Portacaval anastomosis results in more widespread alterations of cerebral metabolism in old versus young adult rats: implications for post-shunt encephalopathy.

Authors:  R M Audet; R F Butterworth
Journal:  Metab Brain Dis       Date:  1998-03       Impact factor: 3.584

Review 4.  The neurosteroid system: an emerging therapeutic target for hepatic encephalopathy.

Authors:  Samir Ahboucha; Roger F Butterworth
Journal:  Metab Brain Dis       Date:  2007-12       Impact factor: 3.584

Review 5.  Neurological implications of urea cycle disorders.

Authors:  A L Gropman; M Summar; J V Leonard
Journal:  J Inherit Metab Dis       Date:  2007-11-23       Impact factor: 4.982

6.  Rats with minimal hepatic encephalopathy due to portacaval shunt show differential increase of translocator protein (18 kDa) binding in different brain areas, which is not affected by chronic MAP-kinase p38 inhibition.

Authors:  Ana Agusti; Jennifer L Dziedzic; Vicente Hernandez-Rabaza; Tomas R Guilarte; Vicente Felipo
Journal:  Metab Brain Dis       Date:  2013-12-04       Impact factor: 3.584

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.